Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial

Omar Khan, Shiyam Nizar, Georgios Vasilikostas, Andrew Wan

Upper Gastrointestinal Surgery Department, St George's Healthcare NHS Trust, London, UK

J Thorac Dis 2012;4(5):465-466. DOI: 10.3978/j.issn.2072-1439.2012.08.16

Although, minimally invasive oesophagectomy was first described in the early 1990s, there is a paucity of high quality data on the relative merits of minimally-invasive versus open oesophagectomy (1,2). This is contrast to colorectal surgery where a number of randomised control trials have conclusively demonstrated the efficacy of laparoscopic colorectal resections (3). The reason for this disparity in evidence base lies in the relative rarity of oesophageal cancers combined with the variety of potential surgical approaches for resection oesophageal cancers (e.g., transhiatal, 2 stage, 3 stage and hybrid laparoscopic approaches). The paper by Beire et al. (4) is therefore very significant addition to the literature on the topic of minimally invasive oesophagectomies. In this multicenter randomised control trial a total of 115 patients underwent either open oesophagectomy through an Ivor Lewis approach or minimally invasive oesophagectomy (MIO) with laparoscopic mobilisation of stomach, thoracoscopic mobilisation of the oesophagus and a cervical oesophagogastrostomy. In terms of the primary outcome of the study, namely respiratory complications, MIO was associated with a reduced incidence of pulmonary infections. In addition MIO was associated with reduced blood loss, reduced post-operative pain, reduced incidences of vocal cord paralysis and a shorter in-hospital stay. This was open label study which meant that the preoperative staging of these patients was not standardisedit is interesting to note that routine PET scanning does not appear to be performed. Nonetheless the fact that majority of the patients underwent preoperative chemoradiotherapy [even though enrollment in this study predated the publication of the

Submitted Jul 25, 2012. Accepted for publication Aug 27, 2012. Available at www.jthoracdis.com

ISSN: 2072-1439 © Pioneer Bioscience Publishing Company. All rights reserved. CROSS group study confirming the efficacy of this neoadjuvant regime (5)] and the impressive R0 resection rate achieved in both the open and minimally invasive groups is a testimony to the high quality of the clinical management of the patients in this study. The authors conclude, in common with previously published non-randomised studies (1,2) that minimally invasive oesophagectomy is associated with significant peri-operative benefits as compared with open oesophagectomy.

It should be noted that the likely perioperative benefits of MIO have in fact been underestimated by this study as the surgeons involved were likely to be on their learning curve. The inclusion criteria for the participating surgeons appears to have the performance of a minimum of only 10 MIOs and this low level of experience may be reflected in relatively high conversion rate of 13%. Moreover, it is likely that the MIO surgical technique will be refined over time. For example, the MIO technique utilised in this study routinely involved a three-stage approach and it is possible over time that this will be refined to a two stage approach - a technique which is technically more demanding but eliminates the need for an additional cervical incision. In addition if the experience of the thoracic surgeons during the development of thoracoscopic surgery is replicated (6), it may be that the MIO patients could be successfully managed with PCAs and paravertebral blocks as opposed to epidurals, thereby eliminating the potential complications associated with this analgesic modality. However, the main issue which this study does not address is that of long-term survival. Advocates of open surgery have long argued that the open approach allows more radical dissection of peri-oesophageal tissue. Interestingly, this argument has been shown to be untrue with regard to laparoscopic rectal surgery- indeed there is some evidence that the reduced systemic inflammatory response associated with laparoscopy may have a positive oncological outcome (7). In this study, the authors noted that the lymph node harvest for the two groups were comparable and the R1 resection rate in the MIO group was in fact the lower than that seen in the open group. The authors therefore conclude that there is no pathological detriment to MIO however they are continuing to follow these

Corresponding to: Omar Khan. Department of Upper GI Surgery, St George's Healthcare NHS Trust, Blackshaw Road, London, SW17 0QT, UK. Email: okhan342@gmail.com.

patients up in order to assess the long term survival. If the authors can indeed demonstrate at least equivalent long-term oncological outcome for MIO and open oesophagectomy, then this paper should provide an impetus for driving forward for the widespread adoption of MIO.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References

- Bailey LA, Khan OA, Reddy M, et al. Does laparoscopic mobilisation of the stomach as part of a trans-thoracic oesophageal resection result in improved peri-operative outcomes as compared with an open approach? Int J Surg 2012. [Epub ahead of print].
- 2. Pradhan C, Khan OA. Does thoracoscopic mobilisation of the oesophagus during oesophageal resection result in improved outcomes as compared to



Cite this article as: Khan O, Nizar S, Vasilikostas G, Wan A. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. J Thorac Dis 2012;4(5):465-466. DOI: 10.3978/j.issn.2072-1439.2012.08.16

open thoracotomy? Int J Surg 2012;10:232-5.

- 3. Aziz O, Constantinides V, Tekkis PP, et al. Laparoscopic versus open surgery for rectal cancer: a meta-analysis. Ann Surg Oncol 2006;13:413-24.
- Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887-92.
- van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
- Fernandez MI, Martin-Ucar AE, Lee HD, et al. Does a thoracic epidural confer any additional benefit following video-assisted thoracoscopic pleurectomy for primary spontaneous pneumothorax? Eur J Cardiothorac Surg 2005;27:671-4.
- Evans C, Galustian C, Kumar D, et al. Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors. Am J Surg 2009;197:238-45.